BTC Selling Pressure Got You Feeling Down? Bitwise CEO Shares His Take on the Latest Bitcoin ETF Milestone!

Hey there, fellow crypto enthusiasts! Let’s Talk About the Spot Bitcoin ETFs, Shall We? So, here’s the scoop: Bitwise CEO Hunter Horsley has stepped up to bat to defend the Spot Bitcoin ETFs after facing some serious heat about these funds supposedly causing Bitcoin’s selling pressure. I mean, come on, can we really blame these…

Read More

Breaking News: Celldex’s Barzolvolimab Proves Successful in Phase 2 Study for Chronic Inducible Urticaria

Celldex Therapeutics Announces Positive Results from Phase 2 Clinical Trial Overview Hampton, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) revealed encouraging outcomes today from their Phase 2 clinical trial of barzolvolimab in chronic inducible urticaria (CIndU). The trial focused on two common forms of CIndU: cold urticaria (ColdU) and symptomatic dermographism…

Read More

Unveiling the Power of Terlivaz: Mallinckrodt’s Groundbreaking Data on Terlipressin for Hepatorenal Syndrome at Kidney Week 2024

Mallinckrodt plc Announces Poster Presentation on TERLIVAZ® at Kidney Week 2024 Introduction Mallinckrodt plc, a global specialty pharmaceutical company, presented a pooled analysis from Phase 3 clinical trials highlighting liver transplant rates in adult patients with Hepatorenal Syndrome (HRS) with rapid reduction in kidney function treated with TERLIVAZ. The presentation took place at Kidney Week…

Read More

Peter Schiff Critiques Microstrategy Shares: The Bitcoin vs. Gold Debate Heats Up

Peter Schiff Declares MicroStrategy Shares as Most Overvalued Stock A Controversial Claim Peter Schiff, a well-known economist and fervent advocate for gold, has raised eyebrows in financial circles by declaring MicroStrategy (MSTR) shares to be “the most overvalued stock” on the market. This assertion comes at a time when the company’s assets have reportedly grown…

Read More

Discover the Exciting Impact of FILSPARI: Travere Therapeutics’ Latest Breakthrough for IgAN and FSGS at ASN Kidney Week 2024!

Exciting Results for FILSPARI in Treatment of IgAN and FSGS New Data Presented at ASN Kidney Week 2024 During the recent American Society of Nephrology (ASN) Kidney Week 2024 conference in San Diego, Travere Therapeutics, Inc. shared new data showcasing the promising clinical benefits of FILSPARI (sparsentan) in the treatment of IgA nephropathy (IgAN) and…

Read More